The overall goal of this research project is to determine how physiological aging of the bone marrow (BM) vascular niche results in a dysregulation of signaling pathways which leads to the disruption of the cellular cross talk between the BM vascular niche and the hematopoietic stem cell (HSC). In this proposal, we aim to define the mechanisms by which age-related alterations to the BM vascular niche can enhance the progression of hematopoietic malignancies. We have demonstrated that Akt signaling in BM endothelial cells (BMECs) supports the maintenance of the HSCs, whereas age-related increases in Mapk and NF-kB signaling promote the differentiation of HSCs into lineage-committed progeny. Our preliminary data demonstrates that the overexpression of Mapk signaling specifically in ECs leads to premature aging (phenotypic and functional) of the HSC and that inhibiting NF-kB signaling in Akt-activated ECs results in a robust in vivo expansion of functional HSCs thereby enhancing hematopoietic recovery following myelosuppression. Additionally, we have found that Akt, Mapk, and NF-kB signaling are upregulated in in vivo BMECs when in contact with AML cells and that Akt-activation in ECs can expand phenotypic leukemia initiating cells leading to aggressive disease. Based on this evidence, we hypothesize that disruption of key signaling pathways in aged BMECs deprive the hematopoietic system from EC-derived instructive signals that are essential for the maintenance and regeneration of non-malignant hematopoietic cells. To formally address this hypothesis, our laboratory has devised novel in vivo and in vitro models that will allow us to determine if modulation of endothelial-specific signaling pathways can safe guard normal HSCs while increasing the susceptibility of the leukemic cells to chemotherapeutic regimens, effectively giving a competitive advantage to the non-malignant hematopoietic system. Utilizing our in vivo mouse models and ex vivo instructive mouse EC/HSC co-culture system that can be utilized to assess the growth potential and aggressiveness of leukemic cells grown on various BMEC lines, we will be able to test 1) if aged BMECs and aberrantly activated (Mapk) BMECs can support the outgrowth of aggressive leukemic clones, 2) if modulation of the Akt/NF-kB signaling axis can reverse age-related hematopoietic defects and give a competitive advantage to non-malignant hematopoietic cells at steady state and following chemotherapeutic intervention, and 3) whether the activation state of the BM endothelium drive the onset of AML using an in vivo genetic mouse model of AML. These studies will begin to unravel the mechanisms by which dysregulation of BMECs in an aged BM microenvironment can lose their instructive capacity to support the proper balance between HSC self-renewal and differentiation. The success of these studies may potentially open up new avenues for the development of a wide array of therapeutic strategies designed as an effective means to diminish leukemic burden and minimal residual disease by augmenting the sensitivity of leukemic cells to chemotherapeutic regimens.

Public Health Relevance

Physiological aging directly leads to a multitude of age-related diseases that affect nearly all systems of the body, including cardiovascular disease, arthritis and cancer. The goal of this proposal is to identify alterations in the aged bone marrow vascular system that facilitates the progression of hematopoietic malignancies. We aim to discovery novel means to modulate vascular cell function to develop therapeutic strategies that could be used as an effective means to reduce the morbidity and mortality associated with chemo/radiological regimens used to treat a wide range of age-related malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA204308-02
Application #
9245630
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Mufson, R Allan
Project Start
2016-04-01
Project End
2021-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
2
Fiscal Year
2017
Total Cost
$345,100
Indirect Cost
$139,225
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Lis, Raphael; Karrasch, Charles C; Poulos, Michael G et al. (2017) Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature 545:439-445
Poulos, Michael G; Ramalingam, Pradeep; Gutkin, Michael C et al. (2017) Endothelial transplantation rejuvenates aged hematopoietic stem cell function. J Clin Invest 127:4163-4178
Ramalingam, Pradeep; Poulos, Michael G; Butler, Jason M (2017) Regulation of the hematopoietic stem cell lifecycle by the endothelial niche. Curr Opin Hematol 24:289-299
Guo, Peipei; Poulos, Michael G; Palikuqi, Brisa et al. (2017) Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Invest 127:4242-4256
Rafii, Shahin; Ginsberg, Michael; Scandura, Joseph et al. (2016) Transplantation of Endothelial Cells to Mitigate Acute and Chronic Radiation Injury to Vital Organs. Radiat Res 186:196-202
Poulos, Michael G; Ramalingam, Pradeep; Gutkin, Michael C et al. (2016) Endothelial-specific inhibition of NF-?B enhances functional haematopoiesis. Nat Commun 7:13829